Inhaled Treprostinil (Tyvaso Nebulizer)
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
COPD (Chronic Obstructive Pulmonary Disease)
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Trial Timeline
Sep 29, 2025 → Jul 1, 2027
NCT ID
NCT07037836About Inhaled Treprostinil (Tyvaso Nebulizer)
Inhaled Treprostinil (Tyvaso Nebulizer) is a phase 2 stage product being developed by United Therapeutics for COPD (Chronic Obstructive Pulmonary Disease). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07037836. Target conditions include COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07037836 | Phase 2 | Recruiting |
Competing Products
20 competing products in COPD (Chronic Obstructive Pulmonary Disease)